Joint Clinical Assessments

Market Access

A dynamic moment for pharma pricing: Insights from PPIC

At PPIC in Basel, pharma pricing experts discussed how policy changes and AI advances are altering the dynamics of pharmaceutical pricing and access.

Market Access

Early strategic evidence planning is a key success factor in...

As the European Union (EU) ushers in a new era of health technology regulation, pharmaceutical companies face both unprecedented challenges and opportunities.

Market Access

The changing landscape of drug clinical assessment: Tommy Br...

In a new pharmaphorum podcast, Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discusses Joint Clinical Assessments.

Market Access

Streamlining JCA response with GenAI

The Joint Clinical Assessment (JCA) framework took effect on 12th January 2025, and its impact is top of mind among pharma innovators today.

Market Access

Managing the challenges and embracing the opportunities of E...

The way HTAs are conducted in Europe is changing. And, if organisations act now to overcome the challenges, they could reap the rewards for years to come.

R&D

Collaborative perseverance to bring change to medicine acces...

Recently, pharmaphorum web editor Nicole Raleigh spoke with Herbert Altmann, head of commercialisation and access solutions Europe at PharmaLex, and Casper Paardekooper, partner at Vintura.

A dynamic moment for pharma pricing: Insights from PPIC

Early strategic evidence planning is a key success factor in...

The changing landscape of drug clinical assessment: Tommy Br...

Streamlining JCA response with GenAI

Managing the challenges and embracing the opportunities of E...

Collaborative perseverance to bring change to medicine acces...

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

Joint Clinical Assessments

Editor's Picks